1. Guidelines provided for the rating of haemostatic efficacy 2. The methods used to categorise FVIII mutations 3. A discussion of the results of epitope analysis 4. Tabulation of characteristics and status of all 55 subjects, including; peak inhibitor titer, ITI , race/ethnicity, family history of inhibitor, intensive treatment at high dose, surgery, port-placement, age at first exposure, high risk HLA, and gene mutation classification (exon, nucleotide change, amino acid change). Bleeding Episode The subject's legally authorised representative (for home infusion) or the investigator/ authorised subinvestigator at the participating site
Rating Scales for Haemostatic Efficacy Assessments

None
No improvement or condition worsens.
Excellent Intraoperative blood loss was lower than or equal to the average predicted blood loss for the type of procedure performed in a haemostatically normal individual of the same sex, age, and stature.
Good Intraoperative blood loss was higher than the average predicted blood loss, but lower or equal to the maximal predicted blood loss for the type of procedure performed in a haemostatically normal individual.
Fair
Intraoperative blood loss was higher than the maximal predicted blood loss for the type of procedure performed in a haemostatically normal individual, but haemostasis was achieved.
Intra-operative haemostatic coverage
The operating surgeon None Haemostasis was uncontrolled in the context of proper dosing, necessitating a change in the clotting factor replacement regimen.
Excellent Postoperative haemostasis achieved with rAHF-PFM was unequivocally as good as or better than that observed with other, licensed FVIII concentrates for the type of surgical procedure performed.
Good
Postoperative haemostasis achieved with rAHF-PFM was probably as good as that observed with other, licensed FVIII concentrates for the type of surgical procedure performed. Any negative impact on the quality of haemostasis achieved with rAHF-PFM was minimal at worst.
Fair
Postoperative haemostasis achieved with rAHF-PFM was clearly less than optimal for the type of procedure performed but was maintained without the need for a change in therapeutic regimen.
Post-operative haemostatic coverage
The investigator None Subject experienced breakthrough bleeding that was the result of inadequate therapeutic response in the face of proper dosing, necessitating a change in therapeutic regimen. a. In subjects below 3 years of age, pain assessments may not be possible.
Method of Categorising Genetic Mutations
For mutation analysis, high molecular mass genomic DNA was isolated from peripheral whole blood according to a salting out procedure (1) A post-hoc, odds ratio (OR) analysis of genetic data was added to the analysis to evaluate genetic mutations as risk factors for inhibitor development. FVIII mutations considered high risk for inhibitor development were large deletion: intron inversion; nonsense; splice site; and frameshift mutations (small deletions/insertions) resulting in a stop codon with no prior documentation of partial correction of reading frame. Mutations considered low risk were missense; in-frame (small deletions/insertions); and frameshift mutations (small deletions/insertions) at or near an A run, previously documented to have partial correction of the reading frame. There is a general consensus of large deletion, nonsense, and inversion (introns 1 and 22) mutations being associated with a high risk and missense mutations being associated with a low risk for inhibitor development (4-9). A high inhibitor risk has recently been reported for splice site mutations, in particular those affecting conserved nucleotide positions(5;7-9). Small deletions/insertions that lead to a frameshift, resulting in a premature stop codon which activates the nonsense mediated decay response, are analogous to a nonsense mutation (10) . In-frame small deletions/insertions are more analogous to a missense mutation and should thus confer a low inhibitor risk. (11) Partial correction of the reading frame for small deletions/insertions at or near adenine stretches (≥8 nucleotides) has been documented at codons 1191-1194 and 1439-1441 (12;13). Outside of these regions, frameshift small deletions/insertions should have a high inhibitor risk, (14) as evidenced by the inhibitor prevalence for mutations outside of A runs in a recent analysis of an expanded cohort (5) . Without empirical data showing that mutations at or near A runs outside of codons 1191-1194 and 1439-1441 have partial correction of the reading frame, partial correction was not assumed, and these mutations were grouped with the other frameshift mutations resulting in a stop codon with no prior documentation of partial correction of reading frame in the present study as having a "high" risk.
Epitope Analysis
To investigate the epitopes of rAHF-PFM recognised by inhibitors, epitope mapping was performed. If an inhibitor was confirmed at the central laboratory, the remaining aliquot(s) of 0.4 mL citrated plasma of the confirmatory test was forwarded to the Labor für Molekulare Hämostaseologie, Klinikum der Johann-Wolfgang-Goethe-Universität, Zentrum für Kinderheilkunde Theodor-Stern-Kai 7, 60596 Frankfurt/Main, Germany, for epitope mapping. If the volume of remaining plasma was not adequate, inhibitor-positive plasma taken from the next available timepoint was to be provided for mapping. The mapping was to be performed by screening random peptide phage displayed libraries as described by Rowley, et al (15) . To map the epitopes as precisely as possible, 3 different libraries were to be screened. The linear peptide sequences were the basis for analysis of conformational epitopes on the 3-dimensional model of FVIII by a software tool (3DEX) (16) .
Epitope binding analysis was performed on plasma samples from 14 of the 16 subjects who developed inhibitors. The results are based on binding studies using phagotopes (epitope mimics on phages) and recombinant FVIII domains (A1, A2, A3, C1, C2). The epitopes identified represent the regions of FVIII that are recognised by total binding antibodies against FVIII. The epitopes for 11 subjects were identified by affinity selection and clustered mainly in the C2 domain (9 subjects), followed by the A2 domain (5 subjects), the A3 domain (3 subjects), and the A1 domain (2 subjects). Only 1 subject was positive for epitope C1. Fourteen subjects were tested for proposed dominant epitopes of antibody binding based on a computer model used for 3-dimensional analysis. Two subjects had proposed dominant epitopes on the A1, A2, and C2 domains, 5 subjects were positive for the C2 epitope. One subject each was proposed for the combined A2 and C1 domains, the combined A2 and C2 domains, and the combined A3 and C2 domains. One subject each had a proposed epitope for the A1 domain and the A2 domain. No dominant epitope data could be determined for 2 subjects.
The A3, C1, and C2 domains are part of a light chain which binds VWF through the C2 domain.
The A2 and A3 domains are necessary for the binding of FVIII to activated factor IX (FIXa).
FVIII inhibitors developed by patients with haemophilia A are most commonly directed against epitopes in the A2 and C2 domains (17) . This is in agreement with results which were obtained in the present study, with 9 subjects positive for C2 and 5 subjects positive for A2.
Conformational epitopes including both A2 and C2 domains identified through computing software were also noted in inhibitor subjects in this study. Table 2 c with no prior documentation of partial correction of reading frame d previously documented to have partial correction of reading frame; small duplication e Subject 33 was labeled missense mutation exon 25 c.A6769G-p.M2238V in results from lab was later determined to be an SNP, the actual mutation was not determined during mutation analysis.
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